Navigation Links
China Biopharma, Inc. Issues Corporate Information Update
Date:12/26/2008

HANGZHOU, China, Dec. 26 /PRNewswire/ -- China Biopharma, Inc. (OTC Bulletin Board: CHBO) issued corporate information updates today.

The Company had significant operational improvement after the start of corporate operational restructuring last year. For the nine months ended September 30, 2008, it has made approximately $5.4 million in sales, more than thirteen times the sales revenue made in the same period of 2007, which was approximately $0.4 million. It also made approximately $90,000 in net profit from the China operation, comparing to a net loss of approximately $0.35 million in the same period of 2007. The Company believes that the current operation will further improve as it finalizes the operational restructuring.

The Company has signed an agreement with Zhejiang Tianyuan Biopharma Co., Ltd. that the Company will increase its stakes from currently 65% to 100% in the joint venture, Zhejiang Tianyuan Biotech Co., Ltd. ("ZTBC"). ZTBC will become a wholly owned subsidiary of the Company, and will change its name to Zhejiang Kangchen Biotech Co., Ltd. It is waiting for the new business license.

The Company has signed an agreement to acquire 90% of Beijing Tiancheng Xinhai Pharmaceutical Co., Ltd. ("BTXP"), a regional pharmaceutical distribution company. The company now has full operating control in BTXP and is waiting for final governmental approval and new business license.

After completion of recent operational restructuring, the company is looking for future merge and acquisitions. The Company is projecting a 25% sales increase in 2009.

About China Biopharma, Inc.

China Biopharma, Inc. is a pharmaceutical company based in China. Through its operating subsidiaries, the company introduces and distributes biopharmaceutical and pharmaceutical products throughout the world's most populated country, China. Products include biopharmaceutical and other pharmaceutical drugs. Leveraging its local presence and the relationship with local Chinese pharmaceutical companies and international pharmaceutical companies, China Biopharma is building a highly-competitive platform for growth in China as well as in new world markets, including the U.S. and Europe. For more information, visit its website at HYPERLINK "http://www.chinabiopharma.net/"http://www.chinabiopharma.net.

Safe Harbor Statement

Some of the statements here discuss future events and developments, including the Company's future business strategy and its ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements can generally be identified by words such as "expect," "anticipate," "believe," "estimate," "intend," "plan," and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company's operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company's new and uncertain business model, uncertainty regarding acceptance of the Company's products and services and the Company's limited operating history.

    CONTACT:

    China Biopharma, Inc.
    Tel: +1 (609) 651-8588
    ir@chinabiopharma.net
   http://www.chinabiopharma.net


'/>"/>
SOURCE China Biopharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Watching water from space could aid disease prevention in China
2. China Sky One Medical, Inc. Obtains Production Rights for Two Additional Drugs
3. Chinas Views on Mental Disorders Improving but Challenges Remain
4. Sinobiopharma Reports Highlights of Third Quarter Results for Its Operating Subsidiary, Dong Ying China
5. China Shenghuo to Resume Trading on NYSE Alternext US LLC
6. China Shenghuo Announces Additional Roll-Out of 12 Ways Cosmetics Products to Watsons Stores
7. China Sky One Medical, Inc. Obtains Production Rights for Two New Drugs
8. Greater China suppliers set to end tough 2008 with strong buyer activity at Global Sources Private Sourcing Events
9. Diagnosis and Drug Treatment of Alzheimers Disease in China is Low and Will Remain Low Through 2012
10. China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO
11. Applied Biosystems – Part of Life Technologies – Helps China Respond to Melamine Contamination in Dairy Products : Government and Industry Increase Contaminant Testing to Increase Food Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... On June ... sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, ... of the city’s history as home to some of the world’s leading providers of ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
Breaking Medicine Technology: